In December 2010, the FDA granted Pfizer's XALKORI NDA Fast Track status, a designation that speeds the review of drugs for serious or life-threatening diseases and for an unmet medical need. Drugs that may offer major advances in treatment or may provide a treatment where no adequate therapy exists usually are given the status. The FDA then granted XALKORI Priority Review status, which shortened the review time from 10 months to six months.
Dr. Charles Rudin, director, Lung Cancer Therapeutics Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a member of LUNGevity Foundation's scientific advisory board said: "Crizotinib is a prime example of successful deployment of a targeted inhibitor against a driver mutation in lung cancer. Like the EGFR inhibitors in EGFR-mutant lung cancer, crizotinib is remarkably effective against ALK-translocated lung cancer." He also pointed out the urgency of additional research, saying, "As with the EGFR inhibitors, acquired resistance to this targeted inhibitor is already emerging as an important problem, and is a focus of ongoing research in the field."
About LUNGevity Foundation
The mission of LUNGevity Foundation is to have a meaningful and immediate impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients, and provide a community for those impacted by lung cancer.
In order to accomplish its mission, LUNGevity funds the most promising research into the early detection and successful treatment of lung cancer. LUNGevity also supports the largest national grassroots lung cancer network.
LUNGevity seeks to inspire the nation to commit to ending lung cancer.
For more information, please visit www.lungevity.org.
About Lung Cancer
|SOURCE LUNGevity Foundation|
Copyright©2010 PR Newswire.
All rights reserved